
Sign up to save your podcasts
Or


The first surge of IPO activity this year sees Alto Neuroscience, ArriVent Biopharma, CG Oncology, Kyverna Therapeutics and Metagenomi making announcements.
Lori, Greg and Tyler also discuss gene therapy pricing including Vertex/CRISPR's Casgevy.
By BioSpace4.9
1313 ratings
The first surge of IPO activity this year sees Alto Neuroscience, ArriVent Biopharma, CG Oncology, Kyverna Therapeutics and Metagenomi making announcements.
Lori, Greg and Tyler also discuss gene therapy pricing including Vertex/CRISPR's Casgevy.

90,841 Listeners

30,817 Listeners

43,710 Listeners

8,760 Listeners

954 Listeners

4,357 Listeners

1,173 Listeners

1,971 Listeners

56,830 Listeners

9,572 Listeners

323 Listeners

6,072 Listeners

6,566 Listeners

34 Listeners

21 Listeners